Our findings demonstrated that NMN promotes intestinal GLP-1 secretion by restoring intestinal NAD+ biosynthesis in HFD-induced obese mice, suggesting that NMN could be a novel therapeutic option for improving postprandial hyperglycemia in obesity. The gene discussed is GCG; the disease is Hyperglycemia.